- Home
- ATAI
as 10-29-2025 4:00pm EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
| Founded: | 2018 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTELVEEN |
| Market Cap: | 1.1B | IPO Year: | 2021 |
| Target Price: | $14.00 | AVG Volume (30 days): | 7.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $6.75 | Next Earning Date: | 11-14-2025 |
| Revenue: | $2,309,000 | Revenue Growth: | 510.85% |
| Revenue Growth (this year): | 736.04% | Revenue Growth (next year): | -91.58% |
Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Apeiron Investment Group Ltd. | ATAI | N/A | Aug 14 '25 | Buy | $2.19 | 8,675,799 | $18,999,999.81 | 51,045,214 |
Latest ATAI Life Sciences N.V. News
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Berenberg Upgrades ATAI Life Sciences to Buy From Positive, Price Target is $12
MT Newswires
9 days ago
Atai Life Sciences Raises $149.5 Million From Public Offering
GlobeNewswire
9 days ago
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Zacks
10 days ago
atai Life Sciences (ATAI) Upgraded to Buy: Here's Why
Simply Wall St.
a month ago
Why Atai Life Sciences (ATAI) Is in Focus After Positive Depression Data and $239M Shelf Registration Filing
Insider Monkey
4 months ago
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Zacks
4 months ago
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Insider Monkey
4 months ago
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating
Compare ATAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.